Primary Site >> Pancreatic Cancer
Gene >> RRM1
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. PMID: 16585222 |
Ref: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. PMID: 17131328 Ref: Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. PMID: 17224927 |
Ref: Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. PMID: 18751396 |
Ref: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. PMID: 19543324 |
Ref: In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. PMID: 19968494 Ref: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. PMID: 20028759 Ref: Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. PMID: 20043067 Ref: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. PMID: 20665488 |
Ref: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. PMID: 21163702 Ref: Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). PMID: 21205085 Ref: Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. PMID: 21264835 Ref: Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. PMID: 21487324 Ref: Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. PMID: 21617862 |
Ref: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. PMID: 21404106 Ref: Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. PMID: 22155850 Ref: Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? PMID: 22436573 Ref: Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. PMID: 22692073 |
Ref: An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implication PMID: 22569992 Ref: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. PMID: 22580602 Ref: Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gem PMID: 23253379 Ref: Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. PMID: 23710668 Ref: Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? PMID: 23905902 Ref: In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. PMID: 23933942 Ref: Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. PMID: 23991987 |
Ref: Pharmacogenetics in neuroendocrine tumors of the pancreas. PMID: 25076325 |
Ref: Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. PMID: 25187316 Ref: Establishment of human pancreatic cancer gemcitabineresistant cell line with ribonucleotide reductase overexpression. PMID: 25394408 Ref: Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. PMID: 25837929 Ref: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). PMID: 26228206 Ref: Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. PMID: 26380056 Ref: ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. PMID: 26557761 |
Ref: MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. PMID: 26828016 Ref: Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. PMID: 27748721 |
Ref: Sclareolide enhances gemcitabineinduced cell death through mediating the NICD and Gli1 pathways in gemcitabineresistant human pancreatic cancer. PMID: 28259943 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. PMID: 28396636 Ref: Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. PMID: 28521448 Ref: MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. PMID: 28887583 Ref: Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization. PMID: 29098031 |
Ref: Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis. PMID: 29214667 Ref: CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. PMID: 29286153 Ref: Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. PMID: 29523831 Ref: Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. PMID: 29983871 Ref: Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer. PMID: 30316690 |